Binge Eating Disorder: Opportunity Analysis and Forecasts to 2027

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Binge Eating Disorder (BED): Executive Summary

2.1 Rapid Growth Expected in the BED Marketplace from 2017–2027

2.2 Targeting Comorbidities Is a Dependable BED Treatment Development Route

2.3 Lack of Awareness Is the Greatest Unmet Need in BED Care

2.4 Dasotraline Expected to Become a Leading Pharmacotherapy for BED by 2027

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for BED (2017–2027)

5.5.1 12-Month Diagnosed Prevalent Cases of BED

5.5.2 Age-Specific 12-Month Diagnosed Prevalent Cases of BED

5.5.3 Sex-Specific 12-Month Diagnosed Prevalent Cases of BED

5.5.4 12-Month Diagnosed Prevalent Cases of BED by BMI

5.5.5 12-Month Diagnosed Prevalent Cases of BED by BMI and Comorbid Mood Disorder

5.5.6 12-Month Diagnosed Prevalent Cases of BED with Substance Abuse Disorder

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Current Treatment Options

6.1 Overview

6.2 Psychotherapy

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved Awareness and Diagnosis of BED

7.3 Larger Pool of Approved BED Pharmacotherapies

7.4 Clinical Evidence for Long-Term Pharmacotherapy Efficacy

7.5 Increased Access to Psychotherapy

8 R&D Strategies

8.1 Overview

8.1.1 Targeting the Brain’s Reward System Receptors

8.1.2 Targeting Key Comorbidities of BED

8.1.3 Repurposing Weight-Loss Therapies

8.2 Clinical Trial Design

8.2.1 Binge Eating or Psychological Endpoints

8.2.2 Psychotherapy Inclusive

8.2.3 Clinical Trial Duration

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Development of Off-Label BED Products

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Generic Erosion

11.3.9 Pricing of Pipeline Agents

11.3.10 Influence of Clinical Evidence on Off-Label Use in BED

11.4 Primary Research – KOLs Interviewed for This Report

11.5 Primary Research – Prescriber Survey

11.6 About the Authors

11.6.1 Analysts

11.6.2 Therapy Area Directors

11.6.3 Epidemiologist

11.6.4 Managing Epidemiologist

11.6.5 Global Director of Therapy Analysis and Epidemiology

11.6.6 Global Head and EVP of Healthcare Operations and Strategy

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Table 1: BED: Key Metrics in the 7MM

Table 2: BED Severity Grading as Defined by DSM-5

Table 3: Risk Factors and Comorbidities for BED

Table 4: Treatment Guidelines for BED

Table 5: Leading Treatments for BED, 2017

Table 6: Comparison of Therapeutic Classes in Development for BED, 2017–2027

Table 7: Approved Drugs in Development for BED, 2018

Table 8: Clinical Benchmark of Key Pipeline Drugs – BED

Table 9: Commercial Benchmark of Key Pipeline Drugs – BED

Table 10: Key Events Impacting Sales for BED, 2017–2027

Table 11: Global Drivers and Barriers in the BED Market, 2017–2027

Table 12: Key Historical and Projected Launch Dates (BED Approval Date in Parentheses)

Table 13: Key Historical and Projected Patent Expiry Dates for BED

Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for BED in 2017 and 2027

Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Vyvanse

Figure 3: Anatomy of the Reward System in the Human Brain

Figure 4: Age-Standardized 12-Month Diagnosed Prevalence of BED in the 7MM, Ages ≥13 Years, 2017

Figure 5: Sources Used and Not Used for Diagnosed Prevalent Cases of BED

Figure 6: Sources Used and Not Used for Diagnosed Prevalent Cases of BED by BMI

Figure 7: Sources Used for Diagnosed Prevalent Cases of BED by BMI and Comorbid Mood Disorder

Figure 8: Sources Used for Diagnosed Prevalent Cases of BED with Substance Abuse Disorder

Figure 9: 12-Month Diagnosed Prevalent Cases of BED, 7MM, Men and Women, Ages ≥13 Years, N, 2017

Figure 10: Age-Specific 12-Month Diagnosed Prevalent Cases of BED, 7MM, Men and Women, Ages ≥13 Years, N, 2017

Figure 11: Sex-Specific 12-Month Diagnosed Prevalent Cases of BED, 7MM, Ages ≥13 Years, N, 2017

Figure 12: 12-Month Diagnosed Prevalent Cases of BED by BMI, 7MM, Men and Women, Ages ≥13 Years, N, 2017

Figure 13: 12-Month Diagnosed Prevalent Cases of BED by BMI and Comorbid Mood Disorder, 7MM, Men and Women, Ages ≥13 Years, N, 2017

Figure 14: 12-Month Diagnosed Prevalent Cases of BED with Substance Abuse Disorder, 7MM, Men and Women, Ages ≥13 Years, N, 2017

Figure 15: Breakdown of the Main Psychotherapy Techniques Applied to BED

Figure 16: Unmet Needs and Opportunities in BED

Figure 17: Overview of the Clinical Development in BED

Figure 18: Key Ongoing Clinical Trials for BED Therapeutics in the 7MM

Figure 19: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Vyvanse

Figure 20: Global (7MM) Sales Forecast by Country for BED in 2017 and 2027

Figure 21: Global Sales Forecast by Class for BED in 2017 and 2027

Figure 22: Sales Forecast by Class for BED in the US in 2017 and 2027

Figure 23: Sales Forecast by Class for BED in the 5EU in 2017 and 2027

Figure 24: Sales Forecast by Class for BED in Japan in 2017 and 2027